Facebook icon Twitter icon Forward icon

Diabetes framework document shows ‘progress’ among CCGs

Clinical commissioning groups (CCGs) across England have made ‘steady progress’, according to a newly published document looking at performance among local diabetes services.

The findings of the CCG Improvement and Assessment Framework (CCG IAF) has shown 86 CCGs are now rated good or outstanding, 26 more than the previous year. To read more, click here

Data collection opens for FreeStyle Libre audit

Data collection for an audit looking to get a real-world view of the FreeStyle Libre (FSL) has now opened.

The Association of British Clinical Diabetologists (ABCD), which represents diabetes consultants in the UK, has launched the analysis as it wants to learn more about device use among adults and young people with both type 1 and type 2 diabetes. To read more, click here

Diabetes consultants urged for final push in annual workforce survey

Diabetes consultants are being urged to take part in an annual workforce survey, with less than a month to go.

One final push is underway to encourage more entries into the Diabetes Workforce Survey, which closes on February 16.

The project, which aims to find out where the nation’s diabetes and endocrine consultants work and the type of job plan they have, is now open. To read more, click here

Scottish type 2 programme ‘effective in delaying insulin’

A 16-week NHS lifestyle programme has been shown to halve the number of people with type 2 diabetes needing to progress to insulin.

A University of Glasgow study has provided evidence that the NHS Greater Glasgow and Clyde Glasgow and Clyde Weight Management Service lifestyle programme can also prevent people from increasing their oral medication for the condition.

The findings also revealed all those who complete the entire programme are more likely to maintain weight loss over a three-year period than those who drop out or are not referred. To read more, click here

UK production ends for major insulin pump brand

People who use the Animas® Vibe® insulin pumps are being urged to speak to their healthcare professional after it was revealed the product is being discontinued immediately.

Animas, the second-largest manufacturer of insulin pumps, has said it will no longer be manufacturing the pump for Europe, following production closure in the US and Canada last year.

Karen Addington, JDRF’s UK chief executive said: “This news is concerning and JDRF is monitoring the situation. It’s important that users are supported by Animas and their healthcare team to identify an alternative pump and ensure a smooth transition to a new medical device.”

To read more, click here